Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 7 7 7 versus AMABELZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 7 7 7 versus AMABELZ.
ALYACEN 7/7/7 vs AMABELZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of norethindrone (progestin) and ethinyl estradiol (estrogen) that inhibits gonadotropin release from the pituitary, suppressing ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
AMABELZ (amenamevir) is a helicase-primase inhibitor that inhibits the viral DNA replication by targeting the helicase-primase complex (UL5/UL52) of herpes simplex virus (HSV) and varicella-zoster virus (VZV).
ALYACEN 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.02 mg and drospirenone 3 mg. One tablet taken orally once daily for 28 days (7 active, 7 placebo, 7 active) without a hormone-free interval.
100 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 14 hours (range 12-16 h) in healthy adults; prolonged to 24-30 h in moderate renal impairment (CrCl 30-50 mL/min).
Terminal half-life of 4-6 hours; clinically relevant for dosing interval of 8-12 hours in normal renal function.
Renal: ~50% (unchanged drug); Fecal: ~20% (via bile); Biliary: ~30% (metabolites). Total clearance is 12 L/h.
Primarily renal (70-80% unchanged), with minor biliary/fecal elimination (10-15%).
Category C
Category C
Oral Contraceptive
Oral Contraceptive